The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities

Italia Anna Asteriti1, Erica Di Cesare1, Fabiola De Mattia1

  • 1Institute of Biology, Molecular Medicine and Nanobiotechnology (formerly Institute of Molecular Biology and Pathology), CNR National Research Council, Sapienza University of Rome, Rome, Italy.

Oncotarget
|August 26, 2014
PubMed

Insights

Aurora kinase inhibitors like MLN8237 impact cell division during mitosis. Cancer cell elimination is inefficient, with dose-dependent effects on aneuploidy, requiring careful therapeutic strategy design.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Aurora kinase inhibition is a promising anti-cancer strategy.
  • Understanding Aurora kinase roles in mitosis is crucial for therapeutic success.
  • MLN8237 is an Aurora-A inhibitor in clinical trials.

Purpose of the Study:

  • To investigate the dose-dependent effects of Aurora-A inhibition on cell division using MLN8237.
  • To elucidate the specific mitotic processes affected by Aurora-A inactivation.
  • To assess the impact of MLN8237 on cell elimination and daughter cell aneuploidy.

Main Methods:

  • Dose-response assays using MLN8237 in U2OS human cancer cells.
  • Synchronous cell cycle progression towards mitosis.
  • Live microscopy to track single-cell behavior and fate during mitosis.

Main Results:

  • MLN8237 affects multiple mitotic processes with differential sensitivity to Aurora-A loss.
  • Aurora-A plays a role in controlling cell division orientation.
  • High-dose MLN8237 treatment does not efficiently eliminate dividing cells or their progeny.
  • Significant aneuploidy is induced in daughter cells, with dose-dependent effects.

Conclusions:

  • MLN8237 exhibits complex, dose-dependent effects on mitosis and cell fate.
  • Inefficient cancer cell elimination and induced aneuploidy necessitate careful consideration for therapeutic strategies.
  • Further research is needed to optimize Aurora kinase inhibitor-based cancer therapies.

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K